(Q36786998)

16 August 2017

1 reference

title

Incretin-based therapies for type 2 diabetes: clinical utility (English)

1 reference

16 August 2017

1 reference

Robert Ratner

1

1 reference

16 August 2017

publication date

1 December 2006

1 reference

Endocrinology and Metabolism Clinics of North America

16 August 2017

published in

1 reference

16 August 2017

volume

35 Suppl 1

1 reference

16 August 2017

page(s)

12-6; discussion 17-19

1 reference

The biology of incretin hormones

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2807%2970005-1

7 January 2021

10.1016/S0889-8529(07)70005-1

Identifiers

DOI

1 reference

16 August 2017

1 reference